Barr Go-Ahead For Generic Ciprofloxacin?
The US Food and Drug Administration has approved Barr Laboratories' application to manufacture and market a generic version of Bayer's Cipro (ciprofloxacin), pending the outcome of an ongoing legal dispute.
Barr is being sued by Bayer AG, along with its US subsidiary Miles Laboratories, over certain patents relating to ciprofloxacin. The suit was filed in a US district court in 1992, after Barr submitted its application dossier to the FDA for approval to market the drug. The FDA approval is effective if Barr wins the case, or when the patent expires in 2002.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze